US Stock MarketDetailed Quotes
BSX Boston Scientific
- 73.345
- +0.085+0.12%
Trading Apr 26 15:28 ET
107.81BMarket Cap61.63P/E (TTM)
73.613High72.695Low6.30MVolume72.995Open73.260Pre Close462.11MTurnover0.43%Turnover Ratio68.55P/E (Static)1.47BShares74.39052wk High5.59P/B107.45BFloat Cap48.35052wk Low--Dividend TTM1.46BShs Float74.390Historical High--Div YieldTTM1.25%Amplitude4.790Historical Low73.318Avg Price1Lot Size
Boston Scientific Stock Forum
Sign in to post a comment
ColumnsOptions Market Statistics: Tesla Stock Jumps on Accelerated Production Plans Despite Earnings Miss
News Highlights
$Tesla(TSLA.US$ shares rose by 1.85%, closing at $144.68. Its options trading volume was 1.75 million. Call contracts account for 44.8% of the total trading volume. The most traded calls are contracts of $160 strike price that expire on Apr. 26th. The total volume reaches 48,736 with an open interest of 28,774. The most traded puts are contracts of a $140 strike price that expires o...
$Tesla(TSLA.US$ shares rose by 1.85%, closing at $144.68. Its options trading volume was 1.75 million. Call contracts account for 44.8% of the total trading volume. The most traded calls are contracts of $160 strike price that expire on Apr. 26th. The total volume reaches 48,736 with an open interest of 28,774. The most traded puts are contracts of a $140 strike price that expires o...
24
2
Insiders selling Boston Scientific shares, even below current price, is discouraging. Yet, high insider ownership could imply company's interest in all shareholders.
1
Boston Scientific's high P/E ratio is attributed to investors' optimism about its strong future growth and market outperformance. Shareholders' confidence in the company's future earnings supports the current P/E ratio and share price.
1
Boston Scientific's EPS growth and insider ownership hint at future success, but investors should note the 2 warning signs. Its strong performance makes it a company to watch.
Piper Sandler analysts find Boston Scientific, Expedia Group, Progressive Corporation, Skechers U.S.A., Synovus Financial, and Zoetis Inc. stocks attractive due to their individual strengths and positive trends.
Meghan Scanlon from Boston Scientific forecasts merger to enhance support for urologists handling chronic conditions. Acquisition may improve earnings per share over time, though GAAP earnings may see lesser increase due to related expenses.
ColumnsToday's Morning Movers and Top Ratings: NVDA, UBER, BSX, UNH and More
Morning Movers
Gapping up
$Fisker(FSR.US$ Shares of the electric vehicle company popped 9.3% after Fisker said that it grew deliveries by over 300% between the third and fourth quarter, helped by strong demand for the company’s Ocean SUV. Fisker said it intends to announce a plan in January to continue accelerating sales and deliveries.
$NVIDIA(NVDA.US$ Nvidia shares ticked 0.3% higher after the chipmaker announced the launc...
Gapping up
$Fisker(FSR.US$ Shares of the electric vehicle company popped 9.3% after Fisker said that it grew deliveries by over 300% between the third and fourth quarter, helped by strong demand for the company’s Ocean SUV. Fisker said it intends to announce a plan in January to continue accelerating sales and deliveries.
$NVIDIA(NVDA.US$ Nvidia shares ticked 0.3% higher after the chipmaker announced the launc...
22
Baird analysts anticipate Insulet's earnings to grow faster than their annual sales of approx. 20%. DexCom's margins predicted to expand with sales growth over 20% annually before GLP-1s impact. Boston Scientific considered a top-level medtech enterprise by Baird's Rescott.
Insiders selling Boston Scientific shares, even below current price, flags unsettling sentiment over company valuation. Absence of insider buying in last year doesn't instill confidence, insider buying would bolster it.
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
104575863 : hai
103625245 : hai guys